|
1. Biologie
|
|
|
Most tumors in body share important mutations [NIH]
|
|
|
|
|
|
Mathematical
modeling of tumor growth and metastases development suggested that the
probability that distinct mutations would drive different metastases
within a given patient is only about 10%. The researchers hope to confirm these results in a larger study, using hundreds of samples taken from dozens of cancer types.
|
|
|
|
|
|
|
2. Etiologie
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
New drug candidate makes cancer cells more sensitive to radiotherapy [Karolinska Institutet]
|
|
|
|
|
|
In
the current study, the researchers discovered that cancer cells use a
protein called PFKFB3 to repair the DNA damage that occurs in radiation
therapy. They found that the protein locates to sites of DNA damage in
the cell nucleus where the protein regulates the cancer cell's ability
to repair its DNA and thus survive. The research groups at Kancera AB
and Karolinska Institutet have now developed a new drug candidate which
blocks the protein and its ability to repair DNA damage.
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.8 Immunothérapies - Economie
|
|
|
|
5.13.1 WCLC - Immunothérapies
|
|
|
|
|
|
|
|
|
|
5.13.2 WCLC - Thérapies ciblées
|
|
|
|
|
|
5.13.3 WCLC - Dépistage
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
TG stock sinks after setback to blood cancer trial [FierceBiotech]
|
|
|
|
|
|
TG
Therapeutics has abandoned plans to seek accelerated FDA approval of
its ublituximab-umbralisib (U2) combination in chronic lymphocytic
leukemia (CLL). The biotech made the decision because its phase 3
overall response rate (ORR) data “were not sufficiently mature to
conduct the analysis.”
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
6.12 Ethique
|
|
|
|
Cancer Center Switches Focus on Fund-Raising as Problems Mount [NY Times]
|
|
|
|
|
|
The
fallout has led medical and academic experts to call for tighter
disclosure rules on potential conflicts of interest in the cancer
research fields and among major nonprofit organizations. Dr. Thompson
and Dr. Lisa DeAngelis, acting physician-in-chief, acknowledged the
issue of low morale in an email to the staff on Monday.
|
|
|
|
|
|
|
6.6 Publications
|
|
|
Next Steps for ORCID and Organization Identifiers [ORCID]
|
|
|
|
|
|
Crossref
and DataCite, together with other stakeholders, are now working on a
proposal to launch and manage an open independent organization
identifier registry. We are pleased that this effort is going forward,
and while we continue to actively support this work, we have decided to
not directly participate for two reasons.
|
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|
Paper Trails: Living and Dying With Fragmented Medical Records [Undark]
|
|
|
|
|
|
I
eagerly await the day a universal electronic health record connects the
dots. But it’s not that day, so we in the health care system must do
everything in our power to deliver good care to those who trust us with
it. We will continue to push papers through fax machines, to wait on
hold as we cold-call those who may provide answers, and to repeat tests
from scratch when we’re stalled. We know it’s not a perfect system. We
know there will be gaps. But what choice do we have?
|
|
|
|
|
|